Showing 1,121 - 1,140 results of 53,189 for search '(( 50 ((a decrease) OR (mean decrease)) ) OR ( a ((non decrease) OR (nn decrease)) ))', query time: 1.17s Refine Results
  1. 1121
  2. 1122

    Apparent Non-Newtonian Behavior of Ionic Liquids by Agnès Piednoir (3780013)

    Published 2020
    “…Depending on the liquid and the rheological conditions, both viscosity increase and decrease have been reported. So far, these variations have been interpreted as a signature of a non-Newtonian behavior. …”
  3. 1123
  4. 1124

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  5. 1125

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  6. 1126

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  7. 1127

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  8. 1128

    Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

    Published 2016
    “…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”
  9. 1129
  10. 1130
  11. 1131
  12. 1132
  13. 1133
  14. 1134
  15. 1135

    Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis by Mei Yang (51996)

    Published 2015
    “…</p><p>Results</p><p>Serum levels of CK-18-M30, FGF-21, IL-1Ra and PEDF increased, while OPG decreased in a stepwise fashion in controls, non-NASH NAFLD patients and NASH patients (<i>P</i> < 0.01). …”
  16. 1136

    Image_1_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.TIF by Hilde L. Orrem (5740313)

    Published 2018
    “…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
  17. 1137

    Image_2_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.TIF by Hilde L. Orrem (5740313)

    Published 2018
    “…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
  18. 1138

    Table_1_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.DOCX by Hilde L. Orrem (5740313)

    Published 2018
    “…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
  19. 1139
  20. 1140